SCHEMBL3335697

SCHEMBL3335697

COC(=O)C1C(Cc2ccnc(N(OC(C)(C)C)C(=O)OC(C)(C)C)c2)C(=O)N1C(=O)Nc1ccccc1Cc1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
F11 P03951 18/20 0.35
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13302750 0.92 F11 (0.37) F11ALDH1A1
SCHEMBL3335695 0.92 F11 (0.37) F11ALDH1A1
SCHEMBL3336436 0.83 F11 (0.41) F11
SCHEMBL3333346 0.83 F11 (0.41) F11
SCHEMBL3334958 0.82 F11 (0.49) F11
SCHEMBL3334953 0.82 F11 (0.49) F11
SCHEMBL13302755 0.82 F11 (0.49) F11
SCHEMBL3334178 0.78 F11 (0.45) F11
SCHEMBL13899661 0.75 FOLH1 (0.43) F11
SCHEMBL13302754 0.75 FOLH1 (0.43) F11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144698-A1 SUBSTITUTED AZETIDINONES DAIAMED (US) 2010-06-10 US disclosed
US-20090143351-A1 SUBSTITUTED AZETIDINONES DAIAMED (US) 2009-06-04 US disclosed
US-7501404-B2 Substituted azetidinones DAIMED (US) 2009-03-10 US disclosed
US-20070105832-A1 Substituted azetidinones Cadrenal Therapeutics, Inc. 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105832-A1 Substituted azetidinones F2R, CPA3, CFD F11 17/4885ALDH1A1 2503/4885
US-20100144698-A1 SUBSTITUTED AZETIDINONES F2R, CPA3, CFD F11 17/4885ALDH1A1 2503/4885
US-20090143351-A1 SUBSTITUTED AZETIDINONES F2R, CPA3, CFD F11 17/4885ALDH1A1 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.